Axitinib is a multitargeted TKI indicated for the treatment of advanced RCC after failure of one prior systemic therapy.
Pertuzumab is a HER2/neu receptor antagonist indicated for the treatment of HER2-positive metastatic breast cancer in combination with trastuzumab and docetaxel in patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Azacitidine is a DNA methylation inhibitor indicated for the treatment of several FAB myelodysplastic syndrome subtypes.
Pazopanib is a tyrosine kinase inhibitor indicated for renal cell carcinoma and advanced soft tissue sarcoma in patients who have received prior chemotherapy.
Vincristine is a vinca alkaloid indicated for the treatment of certain cancers, and may also be used in some combination therapies.
Vemurafenib is a B-RAF enzyme inhibitor indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E mutation.
Cabazitaxel is a taxane derivative indicated to treat hormone-refractory metastatic prostate cancer in patients previously treated with docetaxel.
Asparaginase Erwinia chrysanthemi is a component of a multiagent regimen for treatment of acute lymphoblastic leukemia.
An antibody-drug conjugate indicated for the treatment of Hodgkin lymphoma and sALCL after failure of prior multiagent regimens.
Methylnaltrexone is a peripheral acting narcotic antagonist, opioid reversing agent. It is indicated for treatment of opioid-induced constipation.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|